N'-叔丁氧羰基-D-赖氨酸叔丁酯盐酸盐 | 201007-86-5

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 赖氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N'-叔丁氧羰基-D-赖氨酸叔丁酯盐酸盐
• 中文别名: N’-叔丁氧羰基-D-赖氨酸叔丁酯盐酸盐
• 英文名称: NH2-D-Lys(Boc)-Ot-Bu*HCl
• 英文别名: tert-butyl N6-(tert-butoxycarbonyl)-D-lysinate hydrochloride；Nε-tert-butyloxycarbonyl-D-lysine tert-butyl ester hydrochloride；NE-tert-butyloxycarbonyl-D-lysine tert-butyl ester hydrochloride；H-D-Lys(boc)-otbu hcl；tert-butyl (2R)-2-amino-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoate;hydrochloride
• CAS: 201007-86-5
• 化学式: C₁₅H₃₀N₂O₄*ClH
• 分子量: 338.875
• InChiKey: TZBPQINFXPIRBX-RFVHGSKJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.77
• 重原子数：
  22
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  90.6
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  N'-叔丁氧羰基-D-赖氨酸叔丁酯盐酸盐 在 N-甲基吗啉 、 sodium tetrahydroborate 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 5.42h， 生成 N-{[4-((2R,3R)-1-(4-chlorophenyl)-3-{[2-(4-chlorophenyl)-2-hydroxyethyl]thio}-4-oxoazetidin-2-yl)phenoxy]acetyl}glycyl-D-lysine
  参考文献：
  名称：

  [EN] DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY
  [FR] DERIVES DIPHENYLAZETIDINONE A ACTIVITE INHIBITRICE DE L'ABSORPTION DU CHOLESTEROL

  摘要：

  化合物的结构式（其中变量基团如定义所示）及其药学上可接受的盐、溶剂合物、该类盐的溶剂合物和它们的前药，以及它们作为治疗高脂血症的胆固醇吸收抑制剂的用途被描述。还描述了它们的制备方法和含有它们的药物组合物。

  公开号：

  WO2005061452A1

文献信息

• Composition for the treatment of damaged tissue
  申请人：Pfizer Inc.

  公开号：US20030199440A1

  公开（公告）日：2003-10-23

  A pharmaceutical for use in damaged tissue, such as wound, treatment (e.g. healing) is described. The pharmaceutical comprising a composition which comprises: (a) a growth factor; and (b) an inhibitor agent; and optionally (c) a pharmaceutically acceptable carrier, diluent or excipient; wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.

  描述了一种用于受损组织，如伤口治疗（例如愈合）的药物。该药物包括包含以下成分的组合物：（a）生长因子；和（b）抑制剂；以及可选的（c）药用载体、稀释剂或赋形剂；其中抑制剂可以抑制至少一种在受损组织，如伤口环境中上调的特定不良蛋白质（例如特定蛋白酶）的作用。
• Identification of potent, nonabsorbable agonists of the calcium-sensing receptor for GI-specific administration
  作者：Steven M. Sparks、Paul K. Spearing、Caroline J. Diaz、David J. Cowan、Channa Jayawickreme、Grace Chen、Thomas J. Rimele、Claudia Generaux、Lindsey T. Harston、Shane G. Roller

  DOI：10.1016/j.bmcl.2017.09.008

  日期：2017.10

  of gastrointestinal nutrient sensing pathways provides a promising a new approach for the treatment of metabolic diseases including diabetes and obesity. The calcium-sensing receptor has been identified as a key receptor involved in mineral and amino acid nutrient sensing and thus is an attractive target for modulation in the intestine. Herein we describe the optimization of gastrointestinally restricted

  胃肠道营养物传感途径的调节为治疗包括糖尿病和肥胖症在内的代谢性疾病提供了一种有希望的新方法。钙敏感受体已被确定为涉及矿物质和氨基酸营养素敏感的关键受体，因此是肠内调节的诱人靶标。在本文中，我们描述了从包含3-氨基吡咯烷的模板开始的胃肠道限制钙敏感受体激动剂的优化，从而确定了GI限制激动剂19（GSK3004774）。
• Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity
  申请人：Alenfalk Susanne

  公开号：US20080064676A1

  公开（公告）日：2008-03-13

  Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  本文描述了化学式(I)的化合物（其中变量基团如定义所示），其药学上可接受的盐、此类盐的溶剂化合物、其前药以及其作为治疗高脂血症的胆固醇吸收抑制剂的用途。本文还描述了其制造工艺和含有它们的制药组合物。
• Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
  申请人：AstraZeneca AB

  公开号：US07871998B2

  公开（公告）日：2011-01-18

  Compounds of formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  本文描述了化学式（I）的化合物：（其中变量基团的定义如下）药学上可接受的盐，其溶剂化物，这些盐的溶剂化物及其前药，并将其用作胆固醇吸收抑制剂，用于治疗高脂血症。还描述了它们的制造过程和含有它们的制药组合物。
• 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
  申请人：AstraZeneca AB

  公开号：US07906502B2

  公开（公告）日：2011-03-15

  Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  本文描述了化学式(I)的化合物（其中变量基团的定义如内部所述），其药学上可接受的盐、这些盐的溶剂化合物、这些盐的溶剂化合物的前药及其作为治疗高脂血症的胆固醇吸收抑制剂的用途。还描述了它们的制造过程和含有它们的制药组合物。